Vol: 195963 shares traded
Vol: 1100127 shares traded
The company has received the approval from the US Food and Drug Administration(USFDA) to manufacture the drug, which is indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic category, in strengths of 5mg, 10mg, 20mg and 40mg (ANDA 202725), it said in a release.
The market size of the product is estimated to be USD 49 million for the 12 months ended September 2012, according to IMS, it said.
The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, it said.
Aurobindo now has a total of 188 ANDA approvals (161 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, the release added.
Shares of Aurobindo were quoting at Rs 187.70 apiece, down 2.24 per cent, in the late afternoon trade on the BSE.